GNF2133
CAS No. 2561414-56-8
GNF2133( —— )
Catalog No. M28282 CAS No. 2561414-56-8
GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 357 | Get Quote |
|
10MG | 530 | Get Quote |
|
25MG | 851 | Get Quote |
|
50MG | 1152 | Get Quote |
|
100MG | 1557 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGNF2133
-
NoteResearch use only, not for human use.
-
Brief DescriptionGNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
-
DescriptionGNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.(In Vitro):GNF2133 has an IC50 of >50 μM for GSK3β. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion.(In Vivo):In Diphtheria toxin A (RIP-DTA) mice, GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion. In CD-1 mice, GNF2133 (30 mg/kg; p.o.) shows moderate plasma exposure and good oral absorption with oral bioavailability of 22.3%. In Wistar Han rat, GNF2133 (30 mg/kg; p.o.) increases in cell proliferation marker Ki67 and insulin and reduces cyclin D1 levels and overall cell density.
-
In Vitro——
-
In VivoGNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%.GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo.GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice.Pharmacokinetic Parameters of GNF2133 in CD-1 mice.CD-1 mice; 30 mg/kg; p.o.. Animal Model:CD-1 mice Dosage:30 mg/kg Administration: P.o.Result:Showed good oral absorption and moderate plasma exposure with oral bioavailability of 22.3%.Animal Model:Wistar Han rat Dosage:30 mg/kg (0.5% methylcellulose + Tween-80)Administration:P.o.; once a day for 5 days Result:Increased cyclin D1 levels and overall cell density, and increased in cell proliferation marker Ki67 and insulin.Animal Model:Diphtheria toxin A (RIP-DTA) miceDosage:3, 10, 30 mg/kg (20 mg/kg doxycycline (Dox) for 5 days)Administration:P.o., once a day for 35 daysResult:Significantly improves glucose disposal capacity and increased insulin secretion.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorVEGFR|Tyrosine Kinases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2561414-56-8
-
Formula Weight434.53
-
Molecular FormulaC24H30N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4 mg/mL (9.21 mM)
-
SMILESO=C(NC1=NC=CC(=C1)C2=CN(C=3C=NC=CC23)C4CCOCC4)N5CCN(CC)CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yukitsuka Kudo, et al. Benzoxazole derivatives. US7910579B2
molnova catalog
related products
-
PS 48
PS 48 has been shown to be a PKB Kinase (PDK1) activator (Kd: 10.3 μM). This compound selectively binds to the PIF-binding pocket of PKB Kinase (PDK1).
-
1,2-Dimyristoyl-sn-g...
1,2-dimyristoyl-sn-glycerol is able to increase AChE activity by 35-40% at concentrations of 25 micrograms/ml in the parasite S. mansoni..
-
rac-NBI-74330
rac-NBI-74330 is an effective and selective CXCR3 antagonist.